

Best Available Copy

2

In the Claims:

Cancel claims 1-3, 14-17 and 64.

Please add the following new claims:

Rule 12b
Bl 5/6
7/21/01
NO:113. 65 80 (New) An isolated polypeptide comprising at least a portion of SEQ ID

sub C1 1 66 81 (New) The isolated polypeptide of claim 80, wherein the polypeptide comprises a sequence recited in any one of SEQ ID NO:554, 558, 562, 566 and 573.

C 2 67 82 (New) An isolated polypeptide comprising at least a portion of a sequence having at least 90% identity to ^{the entirety of} SEQ ID NO:113, wherein the polypeptide is over-expressed in prostate tissue compared to all other normal tissues.

ins C2 3 68 83 (New) The isolated polypeptide of claim 82, wherein the polypeptide comprises a sequence having at least 90% identity to a sequence recited in any one of SEQ ID NO:554, 558, 562, 566 and 573, and wherein the polypeptide is over-expressed in prostate tissue compared to all other normal tissues.

4 69 84 (New) An isolated polypeptide comprising at least a portion of a sequence having at least 95% identity to ^{the entirety of} SEQ ID NO:113, wherein the polypeptide is over-expressed in prostate tissue compared to all other normal tissues.

ins C3 5 70 85 (New) The isolated polypeptide of claim 82, wherein the polypeptide comprises a sequence having at least 95% identity to a sequence recited in any one of SEQ ID NO:554, 558, 562, 566 and 573, and wherein the polypeptide is over-expressed in prostate tissue compared to all other normal tissues.

71 86 (New) A composition comprising a polypeptide according to any one of claims 82-85, in combination with a non-specific immune response enhancer.

67-70

330

B